Break the COVID-19 Chain #BreaktheChainBCN

Prevention is as important as treatment in a pandemic. Get involved in this crowdfunding campaign and help us find through this study if Ivermectin reduces the contagions and if it has any effect on the COVID-19 treatment

CROWDFUNDING – MIGRANODEARENA

We believe we hold the key to controlling the spread of the coronavirus. Help us by participating in the crowdfunding campaign for our study! #coronaretos

Tomás Pérez Porcuna, a doctor in infectious diseases and tropical medicine explains to us what is Ivermectin and its effect in relation to the virus of the COVID-19.

Description of the Study:

  • Title: Clinical Trial of Ivermectin for the Treatment and Prophylaxis of COVID-19.
  • Principal Investigator: Tomás Pérez Porcuna.
  • Center of Implementation: Fundació Assistencial Mútua Terrassa.

Objectives of the Study:

Principal Objective: Prove the effectiveness of Ivermectin in the prophylaxis and treatment of COVID-19.

The reduction of COVID-19 transmission between patients is essential in order to control the virus, at least until a vaccine or an effective treatment is found. This research group is currently planning to study the use of Ivermectin which has tremendous potential in reducing COVID-19 transmission. Hence, by collaborating in the crowdfunding campaign for this study you will be contributing to finding out whether Ivermectin can be used to prevent COVID-19.

More about this Study:

Ivermectin is an antibiotic that is currently used to treat parasitic infections and has reportedly shown the ability to inhibit the replication of the virus in-vitro. But what makes Ivermectin so special? It is an active drug that is more than 40 years old, it is cheap and easy to find worldwide. More than 50 million people take it every year, proving it to have a good safety profile, making it an ideal candidate.

This study is authorized by the Spanish Agency of the Medicine (Identifier 20-0333) and by the Ethical Committee of Investigation with Medicine of Fundació Assistencial Mútua Terrassa (date 29/4/2020). Registered in the European Agency for Clinical Trials with the number EUDRA-CT: 2020-001994-66Y.

Fundació Assistencial Mútua Terrassa has an extensive network of primary care centers and a high-tech hospital equipped with all specialties and all means for diagnosis, with a permanent emergency service and complete outpatient clinics. In addition, it offers concerted public health, hospital, and primary care coverage.

Fundaciodocenciarecerca

Other Studies about Pharmacology:

E-speranza-COVID19 Project

This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.

CIBERESUCI COVID

CIBERES UCI COVID is a fundamental study that will improve care of critical patients infected by COVID-19.

Vaccination In People With Long COVID

This study aims to determine the effects of vaccination against SARS-CoV-2 in people with long COVID.

ANTICOV Study: COVID-19 in Africa

Collaborate with ANTICOV study to treat COVID-19 in Africa.

Pexels Pixabay 159211

Antibiotic prescription during the COVID-19 pandemic

Antimicrobial stewardship approaches urgently need to be reinforced during the COVID-19 pandemic. This study evaluates the impact of the COVID-19 on antibiotic consumption.

Antihistamines and azithromycin as a treatment for COVID-19

This study suggests that primary care diagnosis and treatment with antihistamines, plus azithromycin in selected cases, may treat COVID-19 and prevent progression to severe disease in elderly patients.

Immunomodulatory Treatment In Patients With Severe Pneumonia COVID-19

Clinical trial to perform immunomodulatory treatment in adult patients with severe COVID-19 pneumonia with the aim of helping to define the standard treatment for this disease.

Real-life Use Of Remdesivir In Hospitalized Patients With COVID-19

This study aims to evaluate in clinical practice the efficacy and safety of remdesivir in patients admitted for COVID-19.

Prevention With Calcifediol Of Respiratory Problems Caused By COVID-19

This multicentre clinical trial aims to demonstrate that treatment with Calcifediol reduces the need for invasive ventilation and Intensive Care Unit admissions and deaths.

Maraviroc in patients hospitalized for COVID-19

Phase II clinical trial evaluating the safety and efficacy of the drug Maraviroc combined with standard therapy versus standard therapy in patients infected with SARS-CoV-2 and hospitalised with COVID-19.